NEIL W. FLANZRAICH - Corporate Board Profile

CHIPOTLE MEXICAN GRILL INC

Filing Date	Source Excerpt
2012-04-09	Neil W. Flanzraich Mr. Flanzraich has been a private investor since February 2006, and as an executive board member also runs a number of privately-owned pharmaceutical companies. From 1998 through its sale in January 2006 to TEVA Pharmaceuticals Industries, Ltd., he served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company. From 1995 to 1998, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm, and from 1981 to 1994, served in various capacities at Syntex Corporation, a pharmaceutical company. Mr. Flanzraich's executive experience has helped him develop outstanding skills in leading and managing strong teams of employees, and in oversight of the growth and financing of businesses in a rapidly-evolving market. His legal background also is valuable to us in the risk management area, and Mr. Flanzraich brings to us extensive experience serving as an independent director of other public and privately-held companies. He is a director of Equity One Inc. (NYSE:EQY) and BELLUS Health Inc. (TSX:BLUS). Mr. Flanzraich was a director of Continucare Corporation until October 2011, a director of Javelin Pharmaceuticals, Inc. until July 2010, and a director of RAE Systems, Inc. until March 2009. Mr. Flanzraich received an A.B. from Harvard College and a J.D. from Harvard Law School. The compensation of each of our independent directors in 2011 is set forth below. Neil W. Flanzraich Fees Earned or Paid in Cash: $71,500 Stock Awards: $85,233 Total: $156,733
2014-03-27	The members of the Audit Committee are Messrs. Baldocchi (Chairperson), Charlesworth and Flanzraich. Our Board of Directors has determined that all of the Audit Committee members meet the enhanced independence standards required of audit committee members by regulations of the SEC, and are financially literate as defined in the listing standards of the NYSE. The Board has further determined that Mr. Baldocchi qualifies as an "Audit Committee Financial Expert" as defined in SEC regulations.
2016-03-24	Mr. Flanzraich was appointed Chairperson of our Compensation Committee in September 2015, and the other members of the committee are Ms. Friedman and Mr. Flynn. Mr. Flanzraich was appointed Lead Director in September 2014. The compensation of each of our non-employee directors in 2015 is set forth below. Neil W. Flanzraich: Fees Earned or Paid in Cash $123,250, Stock Awards $120,075, Total $243,325.
2017-03-30	The members of the Compensation Committee are Mr. Flanzraich (Chairperson), Ms. Friedman and Mr. Flynn. ... Neil W. Flanzraich total compensation in 2016 was $280,560.
2018-03-30	Neil W. Flanzraich, Age: 74, Director Since: 2007. Executive Chairman of Cantex Pharmaceuticals. Lead Independent Director. Chairperson of the Compensation Committee. Serves on Audit Committee and Nominating and Corporate Governance Committee. Compensation: $294,598.
2019-03-29	Neil W. Flanzraich, Age: 75, Director Since: 2007. Mr. Flanzraich is Executive Chairman of Cantex Pharmaceuticals. The Compensation Committee members are Messrs. Flanzraich (Chairperson), Namvar and Paull. The Nominating and Corporate Governance Committee members are Messrs. Cappuccio (Chairperson), Flanzraich and Namvar. Compensation: $286,563.
2020-04-07	Neil W. Flanzraich, Age: 76, Director Since: 2007. Mr. Flanzraich is the Lead Independent Director and Chair of the Compensation Committee. The members of the Compensation Committee are Messrs. Flanzraich (Chairperson), Namvar, Paull and Ms. Fili-Krushel. The members of the Nominating and Corporate Governance Committee are Messrs. Cappuccio (Chairperson), Flanzraich, Namvar and Ms. Hickenlooper. Director compensation for 2019: Neil W. Flanzraich $335,650.
2021-04-05	Neil W. Flanzraich Age: 77 Director Since: 2007 Mr. Flanzraich is the Executive Chairman of Cantex Pharmaceuticals, Inc. (formerly ParinGenix, Inc.), a privately-owned biotech company, where he previously served as Chief Executive Officer and Chairman, and Executive Chairman of Alzheon, Inc., a privately-owned biotech company. He has been a private investor since February 2006. From 1998 through its sale to TEVA Pharmaceuticals Industries, Ltd. in January 2006, he served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company. From 1995 to 1998, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm, and from 1981 to 1994, served as Senior Vice President, General Counsel and member of the Operating and Executive Committees of Syntex Corporation, an international pharmaceutical company. Mr. Flanzraich serves as Chairman of Atlantix Care Corporation, a privately-owned healthcare provider; Chairman and Co-Founder of AgoneX Biopharmaceuticals, Inc., a privately owned biotech company; and a member of the Board of Directors of Atrium European Real Estate Limited, an owner/manager of shopping centers in Central and Eastern Europe. He previously served as a director and as Lead Independent Director of Equity One Inc., and as a director of a number of other public and private companies. He received an A.B. from Harvard College and a J.D. from Harvard Law School. The Compensation Committee members are Messrs. Flanzraich (Chairperson), Engles, Gutierrez and Namvar, and Ms. Fili-Krushel. The compensation we paid to each non-employee director who served on the Board in 2020 is set forth below. Neil W. Flanzraich: $178,750 fees earned or paid in cash, $207,870 stock awards, total $386,620.